These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 18539965)
1. Prostate cancer stem cells: a new target for therapy. Maitland NJ; Collins AT J Clin Oncol; 2008 Jun; 26(17):2862-70. PubMed ID: 18539965 [TBL] [Abstract][Full Text] [Related]
2. Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. Bizzarro V; Belvedere R; Milone MR; Pucci B; Lombardi R; Bruzzese F; Popolo A; Parente L; Budillon A; Petrella A Oncotarget; 2015 Sep; 6(28):25076-92. PubMed ID: 26312765 [TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy. Leão R; Domingos C; Figueiredo A; Hamilton R; Tabori U; Castelo-Branco P Urol Int; 2017; 99(2):125-136. PubMed ID: 28142149 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. Kanwal R; Shukla S; Walker E; Gupta S Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627 [TBL] [Abstract][Full Text] [Related]
5. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984 [TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986 [TBL] [Abstract][Full Text] [Related]
7. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer stem cells: do they have a basal or luminal phenotype? Maitland NJ; Frame FM; Polson ES; Lewis JL; Collins AT Horm Cancer; 2011 Feb; 2(1):47-61. PubMed ID: 21761340 [TBL] [Abstract][Full Text] [Related]
9. Metformin and prostate cancer stem cells: a novel therapeutic target. Mayer MJ; Klotz LH; Venkateswaran V Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):303-9. PubMed ID: 26215782 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer stem cells: the role of androgen and estrogen receptors. Di Zazzo E; Galasso G; Giovannelli P; Di Donato M; Di Santi A; Cernera G; Rossi V; Abbondanza C; Moncharmont B; Sinisi AA; Castoria G; Migliaccio A Oncotarget; 2016 Jan; 7(1):193-208. PubMed ID: 26506594 [TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646 [TBL] [Abstract][Full Text] [Related]
12. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. Yun EJ; Zhou J; Lin CJ; Hernandez E; Fazli L; Gleave M; Hsieh JT Clin Cancer Res; 2016 Feb; 22(3):670-9. PubMed ID: 26490309 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Paranjape AN; Soundararajan R; Werden SJ; Joseph R; Taube JH; Liu H; Rodriguez-Canales J; Sphyris N; Wistuba I; Miura N; Dhillon J; Mahajan N; Mahajan K; Chang JT; Ittmann M; Maity SN; Logothetis C; Tang DG; Mani SA Oncogene; 2016 Nov; 35(46):5963-5976. PubMed ID: 26804168 [TBL] [Abstract][Full Text] [Related]
14. Identification of a subpopulation of long-term tumor-initiating cells in colon cancer. Peng L; Xiong Y; Wang R; Xiang L; Zhou H; Gu H Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729895 [TBL] [Abstract][Full Text] [Related]
15. Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease. Hoogland AM; Verhoef EI; Roobol MJ; Schröder FH; Wildhagen MF; van der Kwast TH; Jenster G; van Leenders GJ Prostate; 2014 May; 74(5):488-96. PubMed ID: 24375374 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Deng Q; Tang DG Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606 [TBL] [Abstract][Full Text] [Related]
17. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells. Gruber M; Handle F; Culig Z Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633 [TBL] [Abstract][Full Text] [Related]